Topotarget and CuraGen initiate Phase I/II clinical trial

28 August - Topotarget A/S and CuraGen Corporation has announced the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, in combination with the anthracycline idarubicin for the treatment of Acute Myeloid Leukemia (AML). Read more

AstraZeneca and Abbot trials advance 

7 September - AstraZeneca and Abbott will proceed to phase III trials of a combination tablet treatment for the improvement of cholesterol levels, targeting the three main cholesterol components. Read more